- Home
- ACI vs BMRN Comparison
ACI vs BMRN Comparison
Compare ACI & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACI
- BMRN
- Stock Information
- Founded
- ACI 1860
- BMRN 1996
- Country
- ACI United States
- BMRN United States
- Employees
- ACI N/A
- BMRN N/A
- Industry
- ACI Food Chains
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ACI Consumer Staples
- BMRN Health Care
- Exchange
- ACI Nasdaq
- BMRN Nasdaq
- Market Cap
- ACI 12.8B
- BMRN 12.1B
- IPO Year
- ACI 2020
- BMRN 1999
- Fundamental
- Price
- ACI $22.50
- BMRN $57.50
- Analyst Decision
- ACI Buy
- BMRN Buy
- Analyst Count
- ACI 12
- BMRN 22
- Target Price
- ACI $24.42
- BMRN $93.43
- AVG Volume (30 Days)
- ACI 5.0M
- BMRN 2.2M
- Earning Date
- ACI 07-15-2025
- BMRN 08-04-2025
- Dividend Yield
- ACI 2.74%
- BMRN N/A
- EPS Growth
- ACI N/A
- BMRN 152.82
- EPS
- ACI 1.64
- BMRN 2.71
- Revenue
- ACI $80,390,900,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- ACI $4.45
- BMRN $12.23
- Revenue Next Year
- ACI $0.73
- BMRN $9.99
- P/E Ratio
- ACI $13.37
- BMRN $21.25
- Revenue Growth
- ACI 1.46
- BMRN 19.36
- 52 Week Low
- ACI $17.00
- BMRN $52.93
- 52 Week High
- ACI $23.20
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- ACI 55.27
- BMRN 55.64
- Support Level
- ACI $21.06
- BMRN $53.76
- Resistance Level
- ACI $22.08
- BMRN $56.25
- Average True Range (ATR)
- ACI 0.40
- BMRN 1.33
- MACD
- ACI 0.07
- BMRN 0.42
- Stochastic Oscillator
- ACI 75.61
- BMRN 86.90
About ACI Albertsons Companies Inc.
Albertsons is the second-largest supermarket operator in the United States with about 2,300 stores across a variety of banners. Around 80% of the firm's sales comes from nonperishable and fresh food, of which 25% comes from its portfolio of private brands. The company operates fuel centers at about 20% of its store locations and pharmacies at 75%. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of the outstanding shares.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.